Moderna, Inc. (MRNA), the Cambridge, Massachusetts-based biotechnology company built around its messenger RNA (mRNA) platform, has delivered one of 2026's most dramatic large-cap runs. After climbing from a 52-week low near $22 to an intraday high above $254, the shares have pulled back to roughly $200 as investors digest late-stage cancer-vaccine data. The central question now is whether MRNA can reclaim the $250 level.
Because nearly every published analyst target for MRNA now sits below the current price, no usable analyst consensus exists to anchor a forward-looking target. The $250 figure is therefore a technical and psychological objective drawn from public market commentary, specifically a retest of the 52-week high of $254.48 and the round-number $250 level, not an analyst consensus.
That analyst picture is unusually cautious. Among ten verifiable targets reviewed, the range runs from Bernstein's $45 to Bank of America's $220, with a mean near $130, well below the market price. Goldman Sachs is at $137, Morgan Stanley at $95, TD Cowen at $90, Citi at $80, and RBC Capital at $130. Only two targets exceed the current price, Bank of America's $220 and Jefferies' $215, and their average of roughly $217.50 is less than 10% above the latest close, providing no meaningful upside anchor.
With shares near $200.10, reaching $250 requires about a 25% gain, a substantial move. The stock has already traded at $254 intraday, so the path is less about discovering new ground and more about rebuilding conviction after a sharp reversal. The pullback followed the leak of full INTerpath-001 results, which showed a 42% reduction in melanoma recurrence risk with a hazard ratio of 0.58 when combined with Merck's Keytruda, solid but below the more bullish expectations embedded in the stock. Restoring momentum toward $250 would likely require positive read-throughs to upcoming renal cell carcinoma and muscle-invasive bladder cancer readouts, along with evidence the oncology pipeline can offset a shrinking COVID-19 franchise.
Technically, MRNA sits between defined zones. Commentary has identified support in the $170 to $177 area, which held during the recent pullback. Above, the 52-week high of $254.48 acts as the key resistance level and breakout area, with $250 serving as the psychological threshold just beneath it. A sustained push above $250 would require clearing that prior high, while a loss of the $170 support level would call the recovery into question.
Analyst targets generally reflect a roughly 12-month research horizon, though the wide dispersion here shows meaningful disagreement. Near-term catalysts include third-quarter earnings on November 6, 2026 and an Analyst Day on November 12, plus subsequent data readouts for the cancer-vaccine franchise across additional tumor types. Investors should watch analyst revisions, guidance on cost discipline and pipeline spend, and any updates on Merck-partnered commercialization.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a high-volatility name like MRNA, where sentiment can shift abruptly on clinical data, these signals can help traders discover opportunities, monitor positions, and spot changing trends more efficiently. Traders looking to complement their own research can explore the signals alongside the pages above.
The $250 target is a technical milestone, a retest of the 52-week high, requiring a substantial gain of roughly 25% from the latest close. The bull case rests on the validated oncology pipeline, the Merck partnership, and index-driven demand, while the bear case points to a data readout that fell short of elevated expectations, persistent losses, and a valuation that already prices in significant success. The unusually wide $45-to-$220 analyst range, with a mean near $130 below the market price, underscores the disagreement. Whether MRNA reaches $250 will depend on the next oncology readouts and earnings guidance, not on any guarantee embedded in a price target.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with BNTX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then BNTX could also see price increases.
| Ticker / NAME | Correlation To MRNA | 1D Price Change % | ||
|---|---|---|---|---|
| MRNA | 100% | -0.47% | ||
| BNTX - MRNA | 60% Loosely correlated | -1.08% | ||
| CRSP - MRNA | 48% Loosely correlated | -5.23% | ||
| NVAX - MRNA | 47% Loosely correlated | -3.72% | ||
| ARCT - MRNA | 46% Loosely correlated | -9.22% | ||
| MRVI - MRNA | 46% Loosely correlated | -7.68% | ||
More | ||||